A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
OHSU’s singular focus on improving health starts with Oregonians and has global impact. We are the only academic health center in Oregon, but we’re also nationally distinct as a university dedicated solely to advancing health sciences.
Washington, District of Columbia Clinical Trial Location
OHSU – Knight Cancer Institute
3485 SW Bond Ave Center for Health and Healing, Building 2,
Portland, OR 97239